vs

Side-by-side financial comparison of Monopar Therapeutics (MNPR) and Youxin Technology Ltd (YAAS). Click either name above to swap in a different company.

Monopar Therapeutics is the larger business by last-quarter revenue ($73.5K vs $39.4K, roughly 1.9× Youxin Technology Ltd). Youxin Technology Ltd runs the higher net margin — -324.8% vs -2334.5%, a 2009.8% gap on every dollar of revenue.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its lead product candidates address unmet oncology medical needs, serving North American markets and partnering with global healthcare and research institutions to advance its development pipeline.

Youxin Technology Ltd is a China-based automotive digital service provider. It operates used car trading platforms, offers new car sales support, auto financing referrals, and after-sales resource matching for consumers and auto industry participants across mainland China, focusing on optimizing vehicle transaction efficiency.

MNPR vs YAAS — Head-to-Head

Bigger by revenue
MNPR
MNPR
1.9× larger
MNPR
$73.5K
$39.4K
YAAS
Higher net margin
YAAS
YAAS
2009.8% more per $
YAAS
-324.8%
-2334.5%
MNPR

Income Statement — Q2 FY2024 vs Q3 FY2025

Metric
MNPR
MNPR
YAAS
YAAS
Revenue
$73.5K
$39.4K
Net Profit
$-1.7M
$-127.9K
Gross Margin
67.9%
Operating Margin
-2434.5%
Net Margin
-2334.5%
-324.8%
Revenue YoY
-42.7%
Net Profit YoY
22.0%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MNPR
MNPR
YAAS
YAAS
Q2 25
$39.4K
Q2 24
$73.5K
Q1 24
$82.2K
Q4 23
$98.1K
Q3 23
$112.3K
Q2 23
$128.2K
Q1 23
$90.5K
Q4 22
$12.7K
Net Profit
MNPR
MNPR
YAAS
YAAS
Q2 25
$-127.9K
Q2 24
$-1.7M
Q1 24
$-1.6M
Q4 23
$-1.8M
Q3 23
$-2.0M
Q2 23
$-2.2M
Q1 23
$-2.4M
Q4 22
Gross Margin
MNPR
MNPR
YAAS
YAAS
Q2 25
67.9%
Q2 24
Q1 24
Q4 23
Q3 23
Q2 23
Q1 23
Q4 22
Operating Margin
MNPR
MNPR
YAAS
YAAS
Q2 25
Q2 24
-2434.5%
Q1 24
-2097.5%
Q4 23
-1949.6%
Q3 23
-1840.4%
Q2 23
-1815.8%
Q1 23
-2790.5%
Q4 22
Net Margin
MNPR
MNPR
YAAS
YAAS
Q2 25
-324.8%
Q2 24
-2334.5%
Q1 24
-1997.5%
Q4 23
-1849.6%
Q3 23
-1740.4%
Q2 23
-1715.8%
Q1 23
-2690.5%
Q4 22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MNPR
MNPR
YAAS
YAAS
Cash + ST InvestmentsLiquidity on hand
$6.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.1M
$-374.6K
Total Assets
$7.2M
$132.2K
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MNPR
MNPR
YAAS
YAAS
Q2 25
Q2 24
$6.1M
Q1 24
$7.8M
Q4 23
$7.3M
Q3 23
$5.5M
Q2 23
$7.2M
Q1 23
$5.7M
Q4 22
$8.2M
Stockholders' Equity
MNPR
MNPR
YAAS
YAAS
Q2 25
$-374.6K
Q2 24
$6.1M
Q1 24
$7.5M
Q4 23
$5.6M
Q3 23
$6.6M
Q2 23
$7.8M
Q1 23
$8.9M
Q4 22
$10.1M
Total Assets
MNPR
MNPR
YAAS
YAAS
Q2 25
$132.2K
Q2 24
$7.2M
Q1 24
$8.9M
Q4 23
$7.3M
Q3 23
$8.6M
Q2 23
$10.3M
Q1 23
$11.8M
Q4 22
$13.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MNPR
MNPR
YAAS
YAAS
Operating Cash FlowLast quarter
$-1.7M
$-88.6K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MNPR
MNPR
YAAS
YAAS
Q2 25
$-88.6K
Q2 24
$-1.7M
Q1 24
$-1.7M
Q4 23
$-1.5M
Q3 23
$-1.9M
Q2 23
$-2.1M
Q1 23
$-2.3M
Q4 22
$-7.2M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons